| Between October 1999 and April 2001, the foundation partnered with [[CoreMatter]] (formerly known as AllCharities.com) and helped establish the use of the Internet as a charitable giving vehicle. The partnership ended shortly thereafter and CoreMatter ceased operations.((//Initiatives.// Kirsch Foundation. Retrieved March 11, 2023, from http://archive.today/2023.03.11-234424/https://www.kirschfoundation.org/who/initiatives.html)) | Between October 1999 and April 2001, the foundation partnered with [[CoreMatter]] (formerly known as AllCharities.com) and helped establish the use of the Internet as a charitable giving vehicle. The partnership ended shortly thereafter and CoreMatter ceased operations.((//Initiatives.// Kirsch Foundation. Retrieved March 11, 2023, from http://archive.today/2023.03.11-234424/https://www.kirschfoundation.org/who/initiatives.html)) |
| In 2000, the foundation invested in [[pharmaceutical_companies:Targesome]], "a biopharmaceutical company engaged in the development of proprietary receptor-targeted agents to treat and diagnose cancer and other diseases." The company initiated a project with [[pharmaceutical_companies:Merck]] which would have seen the companies co-develop a cancer treatment. Targesome's founder published a paper on the company's work in June 2002 titled //Tumor Regression by Targeted Gene Delivery to the Neovasculature//.((Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002). //Tumor Regression by Targeted Gene Delivery to the Neovasculature.// Science, 296(5577), 2404–2407. https://doi.org/10.1126/science.1070200)) | In 2000, the foundation invested in [[pharmaceutical_companies:Targesome]], a biopharmaceutical company engaged in the development of proprietary receptor-targeted agents to treat and diagnose cancer and other diseases.((Kirsch, S. //Targesome donation.// SKirsch. Retrieved March 11, 2023, from http://archive.today/2023.03.11-234238/https://www.skirsch.com/charity/medical/targesome_donation.htm)) The company initiated a project with [[pharmaceutical_companies:Merck]] which would have seen the companies co-develop a cancer treatment. Targesome's founder published a paper on the company's work in June 2002 titled //Tumor Regression by Targeted Gene Delivery to the Neovasculature//.((Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002). //Tumor Regression by Targeted Gene Delivery to the Neovasculature.// Science, 296(5577), 2404–2407. https://doi.org/10.1126/science.1070200)) |
| In April 2001, the foundation made a $250,000 investment in [[LearnNow]]. After the company was acquired in July 2001 by [[Edison Schools]], the foundation sold off the majority of its stake. | In April 2001, the foundation made a $250,000 investment in [[LearnNow]]. After the company was acquired in July 2001 by [[Edison Schools]], the foundation sold off the majority of its stake. |
